A Double-Blind, Randomized, 3 Period Crossover, Single Ascending Dose Study to Assess the Safety, and Tolerability of Inhaled MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2012
At a glance
- Drugs MDT 637 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 28 Sep 2012 Primary endpoint of safety has been met, according to a MicroDose Therapeutx media release.
- 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History